期刊文献+

进展性肺纤维化的血清标志物研究进展

Research progress in serum markers of progressive pulmonary fibrosis
下载PDF
导出
摘要 在肺间质性疾病中,除特发性肺纤维化外,另有一部分疾病经过积极治疗后,肺部纤维化程度仍然继续加重,导致肺功能进行性降低且早期死亡风险增加,将这一类具有进行性肺纤维化表型的疾病统称为进行性纤维化性间质性肺疾病。其病因复杂,诊断和治疗难度大,近年来,关于各种肺纤维化相关的生物标志物进行了很多探索,发现其在肺纤维化疾病诊断、病情评估、病情监测中均有一定的临床价值,本文对进展性肺纤维化相关的血清学标志物进行总结和分析,提高对相关血清学标志物的进一步认识和临床应用。 In addition to idiopathic pulmonary fibrosis,the degree of pulmonary fibrosis of some interstitial lung diseases continues to worsen after active treatment.This leads to progressive reduction in lung function and increased risk of early death.This kind of disease with progressive pulmonary fibrosis phenotype is referred to as a general name of progressive fibrotic interstitial lung disease.The etiology of pulmonary fibrosis is complex.Their diagnosis and treatment are difficult.In recent years,a lot of exploration has been conducted on various biomarkers related to pulmonary fibrosis.It has been found that these markers have certain clinical value in the diagnosis,disease evaluation and disease monitoring.This article summarizes and analyzes the serological markers related to progressive pulmonary fibrosis in order to improve the further understanding and clinical application of these markers.
作者 于佳 籍佳琦 何星 郭璐 YU Jia;JI Jia-qi;HE Xing;GUO Lu(Chengdu Medical College,Chengdu 610500,China;Department of Pulmonary and Critical Care Medicine,Sichuan Academy of Medical Sciences&Sichuan Provincial People's Hospital,Chengdu 610072,China)
出处 《实用医院临床杂志》 2024年第2期13-16,共4页 Practical Journal of Clinical Medicine
基金 四川省人民医院临床研究及转化基金项目(编号:2018LY07) 四川省医疗卫生与健康促进会科研课题(编号:KY2022SJ0116) 成都市科技局重大科技应用示范项目(编号:2022-YF09-00003-SN)。
关键词 进展性肺纤维化 血清学标志物 研究进展 Progressive pulmonary fibrosis Serological markers Research progress
  • 相关文献

参考文献1

二级参考文献13

  • 1卢昕,谢瑶,王国春.血清KL-6检测在特发性炎性肌病伴肺间质病变诊断中的价值[J].中华风湿病学杂志,2006,10(7):416-419. 被引量:16
  • 2Saketkoo LA, Ascherman DP, Cottin V, et al. Interstitial lung disease in idiopathic inflammatory myopathy. Curr Rheumatol Rev, 2010, 22:633-638.
  • 3Hermans C, Bernard A. Lung epithelium-specific proteins. Characteristics and potential applications as markers. Am J Respir Crit Care Med, 1999,159:646-678.
  • 4Ihn H, Asano Y, Kubo M, et al. Clinical significance of serum surfactant protein D (SP-D) in patients with polymyositis/ dermato myositis: correlation with interstitial lung disease. Rheumatology, 2002, 41 : 1268-1272.
  • 5Marie I, Hachulla E, Cherin P, et al. Interstitial lung disease in polymyositis and dermatomyositis. Arthritis Rheum, 2002, 47: 614-622.
  • 6Kubo M, Ihn H, Yamane K, et al. Serum KL-6 in adult patients with polymyositis and dermatomyositis. Rheumatology, 2000, 39 : 632-636.
  • 7Ishii H, Mukae H, Kadota J, et al. High serum concentrations of surfactant protein A in usual interstitial pneumonia compared with non-specific interstitial pneumonia. Thorax, 2003,58:52-57.
  • 8Chmneos ZC, Chmneos ZS, Shepherd VL. Pulmonary Surfactant: An Immunological Perspective. Cell Physiol Biochem, 2010,25: 13-26.
  • 9Ohnishi H,Yokoyama A, Kondo K, et al. Comparative Study of KL-6, Surfaetant Protein-A, Surfaetant Protein-D, and Monocyte Chemoattractant Protein-1 as Serum Markers for Interstitial Lung Diseases. Am J Resp Crit Care, 2002, 165:378-381.
  • 10Kumtinovics G, Minier T, Radics J, et al. Comprehensive investigation of novel serum markers of pulmonary fibrosis associated with systemic sclerosis and dermato/polymyositis. Clin Exp Rheumatol, 2008,26:414-420.

共引文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部